These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 25560982)

  • 41. The SGLT2 Inhibitor Dapagliflozin Reduces Liver Fat but Does Not Affect Tissue Insulin Sensitivity: A Randomized, Double-Blind, Placebo-Controlled Study With 8-Week Treatment in Type 2 Diabetes Patients.
    Latva-Rasku A; Honka MJ; Kullberg J; Mononen N; Lehtimäki T; Saltevo J; Kirjavainen AK; Saunavaara V; Iozzo P; Johansson L; Oscarsson J; Hannukainen JC; Nuutila P
    Diabetes Care; 2019 May; 42(5):931-937. PubMed ID: 30885955
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cost-effectiveness analysis of dapagliflozin versus glimepiride as monotherapy in a Chinese population with type 2 diabetes mellitus.
    Shao H; Zhai S; Zou D; Mir MU; Zawadzki NK; Shi Q; Liu S; Shi L
    Curr Med Res Opin; 2017 Feb; 33(2):359-369. PubMed ID: 27817216
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Empagliflozin for the treatment of Type 2 diabetes.
    Gangadharan Komala M; Mather A
    Expert Rev Clin Pharmacol; 2014 May; 7(3):271-9. PubMed ID: 24716752
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A paradigm shift in diabetes therapy--dapagliflozin and other SGLT2 inhibitors.
    Chao EC
    Discov Med; 2011 Mar; 11(58):255-63. PubMed ID: 21447284
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cardiovascular mortality and morbidity in patients with type 2 diabetes following initiation of sodium-glucose co-transporter-2 inhibitors versus other glucose-lowering drugs (CVD-REAL Nordic): a multinational observational analysis.
    Birkeland KI; Jørgensen ME; Carstensen B; Persson F; Gulseth HL; Thuresson M; Fenici P; Nathanson D; Nyström T; Eriksson JW; Bodegård J; Norhammar A
    Lancet Diabetes Endocrinol; 2017 Sep; 5(9):709-717. PubMed ID: 28781064
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cost-Effectiveness of Dapagliflozin as Add-On to Metformin for the Treatment of Type 2 Diabetes Mellitus in Greece.
    Tzanetakos C; Tentolouris N; Kourlaba G; Maniadakis N
    Clin Drug Investig; 2016 Aug; 36(8):649-59. PubMed ID: 27221806
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Dapagliflozin, an oral sodium glucose cotransporter type 2 inhibitor for the treatment of type 2 diabetes mellitus.
    Calado J
    IDrugs; 2009 Dec; 12(12):785-98. PubMed ID: 19943222
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Dapagliflozin: potential beneficial effects in the prevention and treatment of renal and cardiovascular complications in patients with type 2 diabetes.
    Fioretto P; Avogaro A
    Expert Opin Pharmacother; 2017 Apr; 18(5):517-527. PubMed ID: 28277831
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Tofogliflozin: first global approval.
    Poole RM; Prossler JE
    Drugs; 2014 Jun; 74(8):939-44. PubMed ID: 24848755
    [TBL] [Abstract][Full Text] [Related]  

  • 50. [Dapagliflozin, a novel oral antidiabetic with an uncertain future].
    Escudero Vilaplana B; Almodóvar Carretón MJ; Herrero Hernández S
    Farm Hosp; 2014 Nov; 38(6):468-74. PubMed ID: 25542657
    [TBL] [Abstract][Full Text] [Related]  

  • 51. NICE guidance on dapagliflozin with insulin for type 1 diabetes.
    Adler AI; Ting S; Dent R; Latimer N
    Lancet Diabetes Endocrinol; 2019 Oct; 7(10):750-751. PubMed ID: 31488391
    [No Abstract]   [Full Text] [Related]  

  • 52. Low-carbohydrate diet combined with SGLT2 inhibitor for refractory hyperglycemia caused by insulin antibodies.
    Shigeno R; Horie I; Ando T; Abiru N; Kawakami A
    Diabetes Res Clin Pract; 2016 Jun; 116():43-5. PubMed ID: 27321315
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Dapagliflozin for type 1 diabetes: ensuring benefits outweigh the risks.
    Erskine D
    Drug Ther Bull; 2020 Mar; 58(3):34. PubMed ID: 32102786
    [No Abstract]   [Full Text] [Related]  

  • 54. Fluorine-Directed Glycosylation Enables the Stereocontrolled Synthesis of Selective SGLT2 Inhibitors for Type II Diabetes.
    Sadurní A; Kehr G; Ahlqvist M; Wernevik J; Sjögren HP; Kankkonen C; Knerr L; Gilmour R
    Chemistry; 2018 Feb; 24(12):2832-2836. PubMed ID: 29211300
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Dapagliflozin for the treatment of type 2 diabetes.
    Abdul-Ghani MA; DeFronzo RA
    Expert Opin Pharmacother; 2013 Aug; 14(12):1695-703. PubMed ID: 23800130
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Implementation of dapagliflozin as adjunctive therapy in type 1 diabetes: A single centre real-world experience.
    Raj A; Bansiya V; Evans ML; Boughton CK
    Diabet Med; 2022 Jun; 39(6):e14764. PubMed ID: 34882842
    [No Abstract]   [Full Text] [Related]  

  • 57. Lansoprazole enhances the antidiabetic effect of dapagliflozin in fortified diet-fed streptozotocin-treated diabetic rats.
    Gamil NM; Abd El Fattah MA; Ahmed MAE; Maklad YA; Gamal El Din AA; Eid NI
    J Biochem Mol Toxicol; 2020 Apr; 34(4):e22451. PubMed ID: 31975531
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Dapagliflozin approved for type 2 diabetes.
    Traynor K
    Am J Health Syst Pharm; 2014 Feb; 71(4):263. PubMed ID: 24481146
    [No Abstract]   [Full Text] [Related]  

  • 59. Dapagliflozin in young people with type 2 diabetes.
    Tommerdahl KL; Nelson RG; Bjornstad P
    Lancet Diabetes Endocrinol; 2022 May; 10(5):303-304. PubMed ID: 35378070
    [No Abstract]   [Full Text] [Related]  

  • 60. Comparison of safety and efficacy of dapagliflozin and empagliflozin in type 2 diabetes mellitus patients in India.
    Varshney A; Rawat R
    Rev Assoc Med Bras (1992); 2023; 69(8):e20230090. PubMed ID: 37585983
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.